The later pandemic years were hard on the biotechnology industry. As inflation rose and costs spiraled, investors shied away, M&A activity tumbled, jobs were cut, and projects shelved. But in the last 12 months, biotech’s outlook has improved considerably.
Rapid technological advancements and groundbreaking innovations – from artificial intelligence to RNA technologies, genetic engineering, and bioprinting – are transforming the sector. This robust innovation pipeline paints a bright picture of the industry’s long-term future, and that’s attracting positive attention.
Clarity of brand, purpose and a strong vision for the future all have critical roles to play.
Exploring the top three challenges faced by BioTech firms:
1
Attracting outside investment
The outlook for the biotechnology industry looks better than it has in years. Investors are showing renewed interest, but they remain cautious. Reputation, credibility, and a clear path to growth will
be critical.
2
M&A
M&A is also on the rise. Are businesses set up effectively to take advantage of potential opportunity?
3
Setting up to win
In an environment of such rapid and transformative change, biotech firms need clarity of direction and a clearly defined positioning to attract investors and buyers alike.
Strategies to unlock growth
Contact Ludo Duursma, Managing Partner, Health, to identify how you can leverage new opportunities in the BioTech sector for business growth.